🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPharmacology & MechanismsGIP receptor pharmacology — anyone have experience? Page 4

GIP receptor pharmacology — anyone have experience?

Dr.RaviCardio Sat, Jan 10, 2026 at 8:15 AM 38 replies 1,386 viewsPage 4 of 8
CarlaRPh_TPA
Senior Member
1,890
8,234
Jan 2024
Tampa, FL
Jan 14, 2026 at 5:22 AM#16

Adding the clinical framing, because it changes how the question reads. Whatever the answer turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, and invite the correction. That is slower than asserting, and it is the only version that survives being wrong.

44 17FDA_TrackerJim, ricardo_MIA, BrianDallas92 and 41 others
Reply Quote Save Share Report
paul_denver
Member
723
3,234
May 2024
Denver, CO
Jan 14, 2026 at 7:25 AM#17
CarlaRPh_TPA said:
Whatever the answer turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, and invite the…

Same experience, arrived at from the opposite direction.

45 18jason_paloalto, Dr.LeslieOBGYN, MikeNYC_runner and 42 others
Reply Quote Save Share Report
dave_SLC
Member
345
1,567
Aug 2024
Salt Lake City, UT
Jan 14, 2026 at 9:28 AM#18
CarlaRPh_TPA said:
Whatever the answer turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, and invite the…

There is a second half to this that has not been said yet. The mechanism is more central than most summaries suggest. Receptor agonism in the arcuate nucleus activates POMC neurons and inhibits AgRP/NPY signalling, and the downstream MC4R pathway is the same one disrupted in monogenic obesity — convergent genetic evidence that the target is the right one. Peripherally there is glucose-dependent insulin secretion, glucagon suppression and delayed gastric emptying, but the gastric component largely adapts over months while the central effect persists, which is why the durable effect is appetite rather than fullness.

Last edited: Jan 14, 2026 at 1:28 PM
46 19james_edin, FranDenver, Dr.BariatricHTX and 43 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
Dr.PathRoch
Member
456
2,123
Jun 2024
Rochester, MN
Jan 14, 2026 at 11:31 AM#19

Adding the numbers, since they settle part of this. Practical: whatever you change, write down the date and the reason. In three months the reason is what you will have forgotten, and the reason is what makes the record worth having.

47 20SaraMom3, Dr.MetabolicMD, RetaRick_CA and 44 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Jan 14, 2026 at 1:34 PM#20

Moderator note: reminder that nothing in this thread is medical advice, and that clinical claims need a source.

19 17PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 16 others
Reply Quote Save Share Report

Similar Threads

GLP-1R desensitization — β-arrestin-mediated internalization18 replies
Biased agonism at GLP-1R — Gs vs β-arrestin signaling balance13 replies
Semaglutide albumin binding and the C-18 fatty acid linker17 replies
GIP receptor pharmacology — why GIP agonism enhances GLP-113 replies
Glucagon receptor signaling — hepatic glycogenolysis and lipolysis16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register